Moderna to Develop Cancer Vaccine with Merck

• 3 min read
Moderna to Develop Cancer Vaccine with Merck

MARKET MOVERS

  • Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients. Moderna’s vaccine, based on its messenger RNA technology, is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer*, in a phase 2 trial. The companies expect to report data in the fourth quarter of this year.

This post is for Market Movers Digest members only.
Subscribe below to get access to this post.
← Bitcoin Falls Below $19,000 After Latest Inflation Report
GM’s Competition With Tesla Heats Up →

Comments

Comments are for paying members only.
Please subscribe or sign in to join the conversation!

Subscribe to Market Movers Digest

Subscribe to emails so you never miss a digest.

You've successfully subscribed to Market Movers Digest
Welcome! You are now a Market Movers Digest subscriber.
Welcome back! You've successfully signed in.
Success! You are now a paying member and have access to all content.
Success! Your billing info is updated.
Billing info update failed.